Topas Therapeutics' Series A - II Round

Topas Therapeutics raised a round of funding on November 03, 2017. Investors include Boehringer Ingelheim Venture Fund.

Topas Therapeutics has developed a unique technology for the induction of antigen-specific immune tolerance. This new approach has the potential to treat autoimmune diseases, allergies and drug induce…

Articles about Topas Therapeutics' Series A - II Round: